Now Click Buy NOW button for 20%off and free same day shipping
Parkinson’s disease is an irreversible nervous system disorder that primarily
affects musculo-skeletal movement. While the progressive disorder can cause stiffness
and slow movements, signs and symptoms vary greatly among patients.
Common symptoms include:
Tremors
Slowed
Movement
Rigid
Muscles
Impaired
balance
Impaired
Posture
Speech
changes
Parkinson’s disease is caused by the gradual breakdown of brain cells called neurons.
The loss of neurons leads to a decrease in dopamine levels, leading to abnormal
brain activity. Only 5% of Parkinson’s cases occur before the age of 40, with
incidence increasing with age. A majority of cases seem to be sporadic and of
unknown origin – however, like most diseases, there is a significant genetic
component.
Recent
theories about the causes of Parkinson’s disease are based on abnormal
fibrin production and deposition in the brain. Also known as the
“amyloid hypothesis,” researchers have been looking at the role of abnormal
protein aggregation in Parkinson’s and other neurodegenerative disorders, like
Alzheimer’s disease. There seems to be a correlation between fibrin deposits
and brain tissue degeneration, suggesting that the fibrin contributes to
cellular death in these diseases. Similar to Alzheimer’s disease and
Huntington’s disease, Parkinson’s disease involves the mis-folding of a
specific protein, eventually leading to fibrin deposits.
There are
several theories as to the underlying cause of Parkinson’s, from oxidative
damage to environmental toxins – but the latest research seeks to understand
why the dopamine-containing neurons are affected so greatly. In fact, by the
time a Parkinson’s patient presents with symptoms, about 70% of the
dopamine-containing neurons have already been lost. Current therapies aim to
address dopamine deficiencies, but future therapies seek to address the
prevention of neuron degeneration (cellular death of the brain cells).
Although systemic enzymes are implicated for the treatment of Alzheimer’s disease,
their use in similar neurodegenerative diseases has yet to be studied.
Specifically nattokinase, which has been shown to directly dissolve the
aggregated protein found in Alzheimer’s disease, may be an option available to
those suffering from Parkinson’s disease.
Nattokinase is a natural systemic enzyme that helps to decrease
fibrin levels in the blood. Nattokinase is also able to reach areas
where fibrin has already accumulated – helping to restore blood flow and
inhibiting cellular death due to oxidative damage. Perhaps the most promising
aspect of systemic enzyme therapy is its ability to be used concurrently with
other medications. The only restriction is upon the use of nattokinase, which
should be discussed with a doctor prior to adding it to a regimen with
prescription blood thinners. However, it should be noted that systemic enzymes
do not cause adverse side effects or drug-drug/drug-nutrient interactions.
